Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for AMFPF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for AMFPF and 80,000+ other tickers.
See exactly how AMFPF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AMFPF and 80,000+ other tickers.
Amplifon SpA engages in the distribution, application, and customization of hearing solutions. It contributes to the development of detection and rehabilitation techniques in otology diagnosis, and management of computerized and integrated auditory systems. It operates through the following geographical segments: Europe, Middle East and Africa (EMEA), Americas, Asia-Pacific, and Corporate. The company was founded by Algernon Charles Holland in 1950 and is headquartered in Milan, Italy.
Amplifon (OTCMKTS:AMFPF - Get Free Report) and Exagen (NASDAQ: XGN - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation. Analyst Ratings This is a breakdown of current ratings and
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amplifon S.p.A. (AMFPY) Q1 2026 Earnings Call Transcript
Franco-Italian eyewear giant EssilorLuxottica looked at investing in Italian hearing aid maker Amplifon in the past, CEO Francesco Milleri said on Tuesday.
Amplifon (OTCMKTS:AMFPF - Get Free Report) and First Choice Healthcare Solutions (OTCMKTS:FCHS - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk. Analyst Recommendations This is a breakdown of